Cost-Utility Analysis of First-Line Regimen Between Cisplatin Plus Pemetrexed and Carboplatin Plus Paclitaxel In Advanced Non-Squamous Non-Small-Cell Lung Cancer in Thailand
Nov 1, 2014, 00:00
10.1016/j.jval.2014.08.118
https://www.valueinhealthjournal.com/article/S1098-3015(14)02048-8/fulltext
Title :
Cost-Utility Analysis of First-Line Regimen Between Cisplatin Plus Pemetrexed and Carboplatin Plus Paclitaxel In Advanced Non-Squamous Non-Small-Cell Lung Cancer in Thailand
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)02048-8&doi=10.1016/j.jval.2014.08.118
First page :
A737
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
2119